FDA Rejects Novo's Tresiba And Ryzodeg
Posted on February 11, 2013 at 12:21 PM EST
The Food and Drug Administration rejected Novo Nordisk's (NYSE: NVO) insulin products Tresiba and Ryzodeg. Shares of the healthcare company plummeted $27.69 to $164.60.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here